β-AGONIST, α1-AGONIST, AND/OR α2-ANTAGONIST TREATMENT OF NEURODEGENERATIVE DISEASES AND CENTRAL NERVOUS SYSTEM TRAUMA

摘要

The treatment of neurodegenerative related pathologies and/or central nervous system trauma by in vivo the stimulation of endogenous or recombinantly expressed nerve growth factor by administration of a therapeutically effective amount of a β-agonist, α1-agonist, and/or α2-antagonist.